Therapeutic Drug Monitoring Market - Forecast(2021 - 2026)

Report Code: HCR 0552 Report Format: PDF + Excel (Delivery in 48 Hrs)
Therapeutic Drug Monitoring Market Overview
Therapeutic Drug Monitoring Market size is estimated to reach $3.17 billion by 2025 and is poised to grow at a CAGR of 6.59% during the forecast period 2020-2025. Therapeutic drug monitoring is used to determine the safe and effective dosage of the drug. Therapeutic Drug Monitoring is used for treatment and for monitoring the concentration of drugs in body fluids, usually plasma. The growing demand for better healthcare facilities in developing countries for a growing urban population is a major factor driving the growth of the global market. In addition, the growth of geriatrics population and the development of innovative tools in drug management, particularly in developing countries, are some of the other factors supporting to the growth of the global market over the forecast period (2020-2025).

Therapeutic Drug Monitoring Market Report Coverage
The report: “Therapeutic Drug Monitoring Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Therapeutic Drug Monitoring Market. 

By Product Type: Consumables and Equipment.
By Drug Class: Anti-epileptic, Antiarrhythmic, Immunosuppressant, Antibiotic, Psychoactive drugs, Bronchodilator.
By Technology: Immunoassays, Chromatography, Proteomic, Spectrophotometry and others.
By End-User: Private labs, Hospitals, Research centers and others.
By Geography: North America, Europe, Asia-Pacific, Rest of World

Key Takeaways
  • Geographically, North America is poised to see extraordinary development owing to well-developed healthcare infrastructure and the presence of major players operating in this region is set to continue its growth during the forecast period (2020-2025).
  • Rising demand for better healthcare facilities and increasing investments in research and developments by private and government organizations are factors driving the market.
  • High infrastructure costs, tight regulatory framework are some of the key factors anticipated to inhibit the growth of the global market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is set to be provided in the Therapeutic Drug Monitoring Market report.

By Product Type- Segment Analysis
The global Therapeutic Drug Monitoring market based on the Product type has Consumables and Equipment. The consumables segment had the largest market share in 2019 and is set to grow at the fastest CAGR during the forecast period 2020-2025. The increasing demand for new technology-based, cost-effective kits and the widespread use of these reagents in the R&D field are some of the factors responsible for its attractive growth.

By Technology – Segment Analysis
Based on Technology, the market is classified into Immunoassays, Chromatography, Proteomic, Spectrophotometry and others. The immunoassay segment dominated the market in 2019 owing to the availability of highly specialized and reliable immunoassays, the increasing adoption rate of advanced technologies and the need for minimal training to handle the equipment. The proteomics segment is set to grow over the forecast period 2020-2025 for a profitable CAGR, owing to the large potential of this technology to interrogate a variety of bio specimens for their proteomes, increasing private and government funding for proteomics-related research activities, and increasing adoption rates of these products in the areas of drug discovery, clinical research and biomarker validation.

By Drug Class – Segment Analysis
Based on Drug-Class, the market is classified into Anti-epileptic, Antiarrhythmic, Immunosuppressant, Antibiotic, Bronchodilator, Psychoactive drugs. The anti-epileptics segment gained the largest market share in 2019 as a result of the increasing prevalence of epilepsy and seizures and resulting the explosive growth in the number of anti-epileptic drugs and is set to continue its growth over the forecast period 2020-2025.

By Geography - Segment Analysis
The North American market is set to dominate the global market in terms of revenue and continue to dominate over the forecast period 2020-2025. Its dominance can be attributed to the well-developed healthcare infrastructure and the presence of key players in the countries of the region. Rapid growth is anticipated in the Asia-Pacific, owing to rising government spending on healthcare infrastructure development and increasing integration and acquisition activities in emerging economies in the region.

Drivers – Therapeutic Drug Monitoring Market 
  • Demand for better Healthcare
The growing demand for better quality healthcare facilities in developing countries for the growing urban population is the main driver behind the growth of the global market. In addition, the increase in the geriatric population, especially in developing countries, and the development of innovative drug management tools are some other factors that are anticipated to drive the growth of the global market. Technological advances and the growing R&D activities of key players are set to create new opportunities in terms of revenue for players operating in the target market over the forecast period (2020-2025).

Challenges – Therapeutic Drug Monitoring Market
  • High cost
The main challenge of this market is the cost of acquiring the Therapeutic Drug Monitoring treatment that is poised to affect the expansion of the market. This is set to hinder market growth over the forecast period (2020-2025). In addition, strict regulatory framework and lack of trained resources are some of the major factors hindering global market growth.

Therapeutic Drug Monitoring Market Industry outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Therapeutic Drug Monitoring Market. Key companies of this market include Abbott Laboratories Inc., Hoffmann-La Roche Ltd, Siemens Healthineers, Inc., Thermo Fisher Scientific Inc., Sekisui Medical Co., Ltd, Buehlmann Laboratories AG, Danaher Corporation, Bio-Rad Laboratories, Inc., bioMérieux S.A, Randox Laboratories Limited.

Acquisitions/Product Launches:
  • In July 2020, Hoffmann-La Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers.
  • In April 2020, Abbott just launched a new test that can tell if you have ever had the coronavirus, and it plans to pump out millions.

1. Therapeutic Drug Monitoring Market - Overview
    1.1 Definitions and Scope
2. Therapeutic Drug Monitoring Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product Type
    2.3 Key trends by Drug Class
    2.4 Key trends by Technology
    2.5 Key trends by End-user
    2.6 Key trends by Geography
3. Therapeutic Drug Monitoring Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies 
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Therapeutic Drug Monitoring Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Therapeutic Drug Monitoring Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Therapeutic Drug Monitoring Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Therapeutic Drug Monitoring Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Therapeutic Drug Monitoring Market – By Product Type (Market Size –$Million/$Billion)
    8.1 Consumables
    8.2 Equipment
9. Therapeutic Drug Monitoring Market – By Drug Class (Market Size –$Million/$Billion)
    9.1 Antiepileptic Drugs
    9.2 Antiarrhythmic Drugs
    9.3 Immunosuppressant Drugs
    9.4 Antibiotic Drugs
    9.5 Bronchodilator Drugs
    9.6 Psychoactive Drugs 
10. Therapeutic Drug Monitoring Market – By Technology (Market Size –$Million/$Billion)
    10.1 Immunoassays
    10.2 Chromatography
    10.3 Proteomic
    10.4 Spectrophotometry
    10.5 Others
11. Therapeutic Drug Monitoring Market – By End-user (Market Size –$Million/$Billion)
    11.1 Private labs
    11.2 Hospitals
    11.3 Research Centers
    11.4 Others
12. Therapeutic Drug Monitoring Market - By Geography (Market Size –$Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 Rest of the World
        12.4.1 Middle East
        12.4.2 Africa
        12.4.3 South America
13. Therapeutic Drug Monitoring Market - Entropy
14. Therapeutic Drug Monitoring Market – Industry/Segment Competition Landscape   (Premium) 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Best Practices for Companies
15. Therapeutic Drug Monitoring Market – Key Company List by Country Premium (Premium)
16. Therapeutic Drug Monitoring Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.